Acta Scientific Cancer Biology

Review Article Volume 4 Issue 1

Fusion of ZNF384 with Different Genes at Acute Lymphoblastic Leukemia Patients

Gazmend Temaj1*, Shefki Xharra2, Kumrije Sopi2, Hilada Nefic3, Angelika Moder4 and Rifat Hadziselimovic3

1Faculty of Pharmacy, University for Business and Technology, Kosovo

2Regional Hospital, Prizren, Kosovo

3Faculty of Natural Sciences, University of Sarajevo, Bosnia and Herzegovina

4Medical Faculty, Paracelsus Medical University, Austria

*Corresponding Author: Gazmend Temaj, Faculty of Pharmacy, University for Business and Technology, Kosovo.

Received: November 11, 2019; Published: December 06, 2019

×

Abstract

  Zinc finger protein 384 (ZNF384) fusion is good indicator in diagnosis; furthermore, ZNF384-rearregment is prevalent in mixed-phenotype acute leukemias. Last time is reported fusion of ZNF384 with 7 other partners in ALL. It is reviews in details the type the types of chromosomal aberrations, their background correlation with immunophenotype and distribution and their prognostic relevance.

KeywordsAcute Lymphoblastic Leukemia; B-Cell; ZNF384; Gene Fusion; Ewing Sarcomas

×

References

  1. Vora A., et al. “Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk andintermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial”. The Lancet Oncology 8 (2014): 809-818.
  2. Vora A., et al. “Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial”. The Lancet Oncology 3 (2013): 199-209.
  3. Goldstone AH., et al. “In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)”. Blood4 (2008): 1827-1833.
  4. Moorman AV., et al. “A population based cytogenetic study of adults with acute lymphoblastic leukemia”. Blood2 (2010): 206-214.
  5. Moorman AV. “The clinical relevance of chromosomal and genomic abnormalities in B cell precursor acute lymphoblastic leukaemia”. Blood Reviews 3 (2012): 123-135.
  6. Bidwell JP., et al. “Involvement of the nuclear matrix in the control of skeletal genes: the NMP1 (YY1), NMP2 (Cbfa1), and NMP4 (Nmp4/CIZ) transcription factors”. Critical Reviews in Eukaryotic Gene Expression 4 (2001): 279-297.
  7. Martini A., et al. “Recurrent rearrangement of the Ewing's sarcoma gene, EWSR1, or its homologue, TAF15, with the transcription factor CIZ/NMP4 in acute leukemia”. Cancer Research 19 (2002): 5408-5412.
  8. Zhong CH., et al. “E2AZNF384 and NOL1-E2A fusion created by a cryptic t (12;19) (p13.3; p13.3) in acute leukemia”. Leukemia 4 (2008): 723-729.
  9. Hirabayashi S., et al. “ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype”. Haematologica1 (2017):118-129.
  10. Busse TM., et al. “Copy number alterations determined by single nucleotide polymorphism array testing in the clinical laboratory are indicative of gene fusions in pediatric cancer patients”. Genes Chromosomes Cancer 10 (2017): 730-749.
  11. Gu Z., et al. “Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia”. Nature Communications 7 (2016): 13331.
  12. Liu YF., et al. “Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia”. EBio Medicine 8 (2016): 173-183.
  13. Yasuda T., et al. “Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults”. Nature Genetics 5 (2016): 569-574.
  14. Suzuki K., et al. “MEF2D-BCL9 fusion gene is associated with high risk acute B-cell precursor lymphoblastic leukemia in adolescents”. Journal of Clinical Oncology 34 (2016): 3451-3459.
  15. Iacobucci I and Mullighan CG. Genetic Basis of Acute Lymphoblastic Leukemia”. Journal of Clinical Oncology 9 (2017): 975-983.
  16. Alexander TB., et al. “The genetic basis and cell of origin of mixed phenotype acute leukaemia”. Nature7727 (2018): 373-379.
  17. Oberley MJ., et al. “MyeloidlineageswitchfollowingchimericantigenreceptorT-celltherapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia”. Pediatric Blood and Cancer 9 (2018): e27265.
  18. Qian M., et al. “Whole transcriptome sequencing identified a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP”. Genome Research 27 (2017): 185-195.
  19. Gocho Y., et al. “Tokyo Children’s Cancer Study, G. A novel recurrent EP300ZNF384 gene fusion in B-cell precursor acute lymphoblastic leukemia”. Leukemia 29 (2015): 2445-2448.
  20. McClure BJ., et al. “Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, isassociated with a distinct gene expression”. British Journal of Cancer 7 (2018):1000-1004.
  21. Haslinger A., et al. “ZNF384 gene fusions in BCP-ALL: A report of twelve Austrian cases secured by systematic FISH and array screening”. Molecular Cytogenetics1 (2019): O11.
  22. Inaba H., et al. “Acute lymphoblastic leukaemia”. Lancet 381 (2013):1943-1955.
×

Citation

Citation: Gazmend Temaj., et al. "Fusion of ZNF384 with Different Genes at Acute Lymphoblastic Leukemia Patients".Acta Scientific Cancer Biology 4.1 (2020): 34-37.



Member In



News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 15, 2020.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US